Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: A prospective cohort study

BMJ Open

Volumn 1, Issue 1, 2011, Pages

  Modrego, Pedro J ^a   Fayed, Nicolas ^b   Sarasa, Manuel ^c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955927184     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2010-000007     Document Type: Article

References (61)

1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
2. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol 2001;58:397-405. (Pubitemid 32217456)
3. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population based cohort. Neurology 2002;59:1594-9. (Pubitemid 35387068)
4. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006;(3):CD006104.
5. Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials. PLoS Med 2007;4:-338.
6. Wolfson C, Oremus M, Shukla V, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002;24:862-86. (Pubitemid 34734735)
7. De León MJ, Golomb J, George AE, et al. The radiologic prediction of Alzheimer's disease: The atrophic hippocampal formation. Am J Neuroradiol 1993;14:897-906. (Pubitemid 23213382)
8. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-403. (Pubitemid 29190530)
9. Killiany RJ, Gómez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000;47:430-9. (Pubitemid 30194598)
10. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild AD. Neurobiol Aging 2001;22:747-54. (Pubitemid 33055614)
11. Visser PJ, Verhey FR, Hofman PA, et al. Medial temporal lobe atrophy predicts Alzheimer's disease in mild cognitive impairment. J Neurol Neurosurg Psychiatry 2002;72:491-7.
12. Korf ES, Wahlund LO, Visser PJ, et al. Medial temporal lobe on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004;63:94-100. (Pubitemid 38943785)
13. De Toledo-Morrell L, Stoub TR, Bulgakova M, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004;25:1197-203. (Pubitemid 39094022)
14. Jack CR, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly with amnestic MCI. Neurology 2005;65:1227-31. (Pubitemid 41508215)
15. Stoub TR, Bulgakova M, Leurgans S, et al. MRI predictors of risk of incident Alzheimer's disease: A longitudinal study. Neurology 2005;64:1520-4. (Pubitemid 40617686)
16. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology 2007;68:828-36. (Pubitemid 46568534)
17. Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer's disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-34. (Pubitemid 35340483)
18. Zatterberg H, Wahlung LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003;352:67-9. (Pubitemid 37412328)
19. Andreasen N, Vanmechelen E, Vanderstichele H, et al. Cerebrospinal fluid levels of total-tau, phospho-tau and A Beta42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 2003;179:47-51.
20. Hampel H, Teipel SJ, Fuchrberger T, et al. Value of CSF-Betaamyloid1- 42 and tau as predictors of Alzheimer's disease in mild cognitive impairment. Mol Psychiatry 2004;9:705-10. (Pubitemid 38932175)
21. Ivanoiu A, Sindic CJ. Cerebrospinal fluid Tau protein and Amyloid- B42 in mild cognitive impairment: Prediction of progression to Alzheimer's disease and correlation with the neurological examination. Neurocase 2005;11:32-9. (Pubitemid 40372858)
22. de Leon MJ, Segal S, Tarshish CY, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 2002;333:183-6. (Pubitemid 35335773)
23. Vanderstichele H, De Meyer G, Andreasen N, et al. Amino-truncated {beta}-Amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650-60. (Pubitemid 41233100)
24. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-93.
25. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-45. (Pubitemid 34465046)
26. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-63. (Pubitemid 44969124)
27. Hunt A, Schonknecht P, Henze M, et al. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res 2007;155:147-54. (Pubitemid 46874914)
28. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001;98:10966-71. (Pubitemid 32878727)
29. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 2004;63:2332-40. (Pubitemid 40024346)
30. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005;46:1625-32. (Pubitemid 46211586)
31. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer's disease. Arch Neurol 2005;62:1728-33. (Pubitemid 41626670)
32. Kantarci K, Petersen RC, Boeve BF, et al. 1H MR spectroscopy in common dementias. Neurology 2004;63:1393-8.
33. Kantarci K, Jack CR, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease. Neurology 2000;55:210-17. (Pubitemid 30604620)
34. Hancu I, Zimmerman EA, Sailasuta N, et al. 1H MR spectroscopy using TE averaged PRESS: A more sensitive technique to detect neurodegeneration associated with Alzheimer's disease. Magn Reson Med 2005;53:777-82. (Pubitemid 40478424)
35. Kantarci K, Xu YC, Shiung MM, et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:198-207. (Pubitemid 36151487)
36. Miller BL, Moats RA, Shonk T, et al. Alzheimer's disease: Depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 1993;187:433-7. (Pubitemid 23127850)
37. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 1995;195:65-72.
38. Rai GS, McConnel JR, Waldman A, et al. Brain proton spectroscopy in dementia: An aid to clinical diagnosis. Lancet 1999;353:1063-4. (Pubitemid 29149917)
39. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005;162:667-75. (Pubitemid 40489127)
40. Fayed N, Davila J, Oliveros A, et al. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversión to probable dementia. Acad Radiol 2008;15:1089-98.
41. Metastasio A, Rinaldi P, Tarducci R, et al. Conversión of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006;27:926-32.
42. Kantarci K, Weigand SD, Przybelski SA, et al. Risk of dementia in MCI. Combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 2009;72:1519-25.
43. Pilatus U, Lais C, Rochmont Adu M, et al. Conversion to dementia in mild cognitive impairment is associated with decline of N-acetylaspartate and creatine as revealed by magnetic resonance spectroscopy. Psychiatry Res 2009;173:1-7.
44. Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the memory impairment screen. Neurology 1999;52:231-8. (Pubitemid 29059044)
45. Lobo A, Ezquerra J, Gomez Burgada F, et al. El Mini-Examen cognoscitivo: Un test sencillo y practico para detectar alteraciones intelectuales en pacientes médicos (in Spanish). Actas Luso Esp Neurol Psiquiatr Cienc Afines 1979;7:189-202.
46. Fayed N, Modrego PJ, Medrano J. Comparative testeretest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software. Neurol Res 2009;31:472-7.
47. Modrego PJ, Fayed N, Errea JM, et al. Memantine versus donepezil in Alzheimer's disease. A randomized trial with magnetic resonance spectroscopy. Eur J Neurol 2010;17:405-12.
48. McKhan G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group. Neurology 1984;34:939-44.
49. Klunk WE, Panchalingam K, Moossy J, et al. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: A preliminary proton nuclear magnetic resonance study. Neurology 1992;42:1578-85.
50. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008;248:210-20.
51. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66:718-22. (Pubitemid 43739827)
52. Kantarci K, Boeve BF, Wszolek Z, et al. MRS in presymptomatic MAPT mutation carriers. Neurology 2010;75:771-8.
53. Bokde AL, Teipel SJ, Drzezga A, et al. Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:352-7. (Pubitemid 41642793)
54. McKee AC, Cabral HJ, Kowall NW, et al. Visual association pathology in preclinical Alzheimer disease. J Neuropathol Exp Neurol 2006;65:621-30. (Pubitemid 44288946)
55. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-8.
56. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 2009;73:754-60.
57. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 2006;3:161-70.
58. Fayed N, Olmos S, Morales H, et al. Physical basis of magnetic resonance spectroscopy and its application to central nervous system diseases. Am J Appl Sci 2006;3:1836-45.
59. Wang Z, Zhao C, Yu L, et al. Regional metabolic changes in the hippocampus and posterior cingulated area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer's disease. Acta Radiol 2009;50:312-19.
60. Caserta MT, Ragin A, Hermida AP, et al. Single voxel MR spectroscopy at 3T in a memory disorders clinic: Early right hippocampal NAA/Cr loss in mildly impaired subjects. Psychiatry Res 2008;164:154-9.
61. Danielsen ER, Ross B. Basic physics of MRS. In: Danielsen ER, Ross B, eds. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York: Marcel Dekker, 1999:5-22.